Treatments for patients with genotype 1 chronic hepatitis C: a review of evidence-based guidelines
CADTH
Record ID 32015000245
English
Authors' recommendations:
The two newest CHC drugs, simeprevir and sofosbuvir, in combination with each other or with other agents (PR, ribavirin or daclatasvir) are currently the recommended treatments for various sub-populations of patients with genotype 1 CHC according to the most recent guidelines. These recommendations are based on randomized controlled trial (RCT) and non-RCT evidence and do not take into consideration cost and cost-effectiveness.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/jul-2014/RC0562%20Hep%20C%20Guidelines%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antiviral Agents
- Drug Therapy, Combination
- Hepatitis C, Chronic
- Sofosbuvir
- Simeprevir
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.